Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2003

View Archived Issues

CAT, Micromet and Enzon sign crosslicense agreement

Reduced mortality associated with pexelizumab in acute myocardial infarction

ALT-711 improves diastolic filling and quality of life in patients with DHF

Ranolazine equally safe and effective in diabetic and nondiabetic patients with angina

Good efficacy and safety profiles described for ivabradine and atenolol in stable angina

Elidel studies reveal patient satisfaction with eczema treatment

Two new phase I trials investigate Xcytrin plus Taxotere for advanced cancers

Provenge receives fast track designation

Phase I trial evaluates safety of AMD-070 for treatment of HIV infection

Theratechnologies signs agreement for use of ExoPep platform

Merck claims new S1P1 receptor agonists with potential as immunosuppressants

New anti-HCV agents in early development at Ribapharm

Toa Eiyo scientists prepare and test novel glucose- and lipid-lowering agents

Dual sigma receptor ligands/AChE inhibitors and their use in psychosis, dementia, etc.

Kyorin patent covers new NK1 antagonists for urinary incontinence and other uses

Micromet to develop CAT's EpCAM-targeting antibody

Microbicide UC-781 enters phase I

Pozen and Xcel sign commercialization agreement for MT-300

Selective anti-H. pylori agent synthesized in China

Positive preclinical results indicate utility of AVI-4179 for treatment of SARS

Promising anti-HIV agent targets HIV-1 envelope protein

Japanese group identifies new antiangiogenic/antimetastatic MMP inhibitor

Continued development of QR-337 to be conducted under IND

Milestone in Vicuron and Novartis peptide deformylase inhibitor collaboration

Bicyclic androgen receptor antagonists pursued at BMS

GW-572016, a dual EGFR/ErbB-2 TK inhibitor, discussed in ACS presentation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...